Literature DB >> 16158403

Minmax designs for planning the second phase in a two-phase case-control study.

W Schill1, P Wild.   

Abstract

Two-phase designs, in which a subsample with validation or complete information data is sampled stratified both on outcome and covariate from a first-phase study with incomplete data, have been proposed over 10 years ago and have been proven to result in efficient estimates with respect to standard designs. The efficiency depends, however, on the sampling fractions within each stratum. Our aim is to present a strategy for obtaining an optimized design, i.e. sampling fractions, that makes use of available phase-one data of an existing case-control study considered as the first-phase sample when the focus is on estimating a parameter vector. No global optimal design exists and local optimal designs depend on scenarios comprising the true disease model and the association between the phase-one and phase-two information. We develop an admissibility test that rejects scenarios inconsistent with the phase-one data and, for the selected scenarios, determine a minmax D- or A-optimal design that protects against worst-case scenarios. This work is applied on two examples. Copyright 2006 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2006        PMID: 16158403     DOI: 10.1002/sim.2307

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.

Authors:  Michelle DeVeaux; Michael Kane; Wei Wei; Daniel Zelterman
Journal:  Pharm Stat       Date:  2019-09-10       Impact factor: 1.894

2.  The cost-effectiveness of reclassification sampling for prevalence estimation.

Authors:  Airat Bekmetjev; Dirk VanBruggen; Brian McLellan; Benjamin DeWinkle; Eric Lunderberg; Nathan Tintle
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

3.  Flexible Two-Phase studies for rare exposures: Feasibility, planning and efficiency issues of a new variant.

Authors:  Pascal Wild; Nadine Andrieu; Alisa M Goldstein; Walter Schill
Journal:  Epidemiol Perspect Innov       Date:  2008-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.